부산대학교 도서관

Yap, Timothy A ; Bjerke, Lynn ; Clarke, Paul A ; Workman, Paul

In Current Opinion in Pharmacology August 2015 23:98-107

Workman, Paul; Al-Lazikani, Bissan; Clarke, Paul A

In Current Opinion in Pharmacology August 2013 13(4):486-496

Zhang C; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Shanghai Institute of Biological Products, Shanghai, China.; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China.; Lu YJ; Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.; Chen B; GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.; Bai Z; Key Laboratory of Synthetic Biology, Ministry of Agriculture and Rural Affairs, Advanced Synthetic Biology Institute at Hohhot, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China.; Zeng Q; Shanghai Institute of Biological Products, Shanghai, China.; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China.; Hervieu A; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Licciardello MP; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Mitsopoulos K; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Al-Lazikani B; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Tortorici M; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.; Rossanese OW; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. olivia.rossanese@icr.ac.uk.; Workman P; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. paul.workman@icr.ac.uk.; Clarke PA; Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. paul.clarke@icr.ac.uk.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Duff LC; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Yilmaz S; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Agora A; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Maddocks CJ; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Fairlamb IJS; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Unsworth WP; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.; Clarke PA; Department of Chemistry, University of York, YO10 5DD, Heslington, York, UK. william.unsworth@york.ac.uk.

Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101154995 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-0539 (Electronic) Linking ISSN: 14770520 NLM ISO Abbreviation: Org Biomol Chem Subsets: MEDLINE; PubMed not MEDLINE

Newman JA; Centre for Medicines Discovery, University of Oxford, Oxford, UK. Joseph.newman@cmd.ox.ac.uk.; Gavard AE; Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Exscientia, Oxford, UK.; Imprachim N; Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.; Aitkenhead H; Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Diamond Light Source Ltd, Didcot, UK.; Sheppard HE; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Sano Genetics Ltd, Cambridge, UK.; Te Poele R; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Clarke PA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Hossain MA; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Temme L; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Institute of Pharmacy, University of Hamburg, Hamburg, Germany.; Oh HJ; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Wells CI; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; GlaxoSmithKline, Collegeville, PA, USA.; Davis-Gilbert ZW; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Workman P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK. paul.workman@icr.ac.uk.; Gileadi O; Centre for Medicines Discovery, University of Oxford, Oxford, UK.; SGC Karolinska, Centre for Molecular Medicine, Stockholm, Sweden.; Drewry DH; SGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. david.drewry@unc.edu.; UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. david.drewry@unc.edu.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

More, David G ; Clarke, Paul A

In International Journal of Medical Informatics 1999 55(1):65-75

Sharp SY; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; Martella M; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; D'Agostino S; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; Milton CI; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; Ward G; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Woodhead AJ; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK. Andrew.Woodhead@astx.com.; Richardson CJ; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK. Caroline.Richardson@astx.com.; Carr MG; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Chiarparin E; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Cons BD; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Coyle J; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; East CE; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Hiscock SD; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Martinez-Fleites C; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Mortenson PN; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Palmer N; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Pathuri P; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Powers MV; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; Saalau SM; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; St Denis JD; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Swabey K; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.; Vinković M; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Walton H; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Williams G; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.; Clarke PA; RNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK. Paul.Clarke@icr.ac.uk.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Dale, Trevor; Clarke, Paul A; Esdar, Christina; Waalboer, Dennis; Adeniji-Popoola, Olajumoke; Ortiz-Ruiz, Maria-Jesus; Mallinger, Aurélie; Samant, Rahul S; Czodrowski, Paul; Musil, Djordje; Schwarz, Daniel; Schneider, Klaus; Stubbs, Mark; Ewan, Ken; Fraser, Elizabeth; TePoele, Robert; Court, Will; Box, Gary; Valenti, Melanie; de Haven Brandon, Alexis

Nature Chemical Biology. Dec2015, Vol. 11 Issue 12, p973-980. 8p.

Ortiz-Ruiz MJ; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Popoola O; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Mitsopoulos K; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Te-Poele R; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Samant RS; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Box G; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Court W; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Brandon AH; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Gowan S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Mallinger A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Roe T; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Swabey K; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Valenti M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Al-Lazikani B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Blagg J; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Esdar C; The Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany.; Schiemann K; The Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany.; Wienke D; The Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany.; Eccles SA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Workman P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Clarke PA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.

Publisher: American Chemical Society Country of Publication: United States NLM ID: 101282906 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1554-8937 (Electronic) Linking ISSN: 15548929 NLM ISO Abbreviation: ACS Chem Biol Subsets: MEDLINE

Polier, Sigrun; Samant, Rahul S; Clarke, Paul A; Workman, Paul; Prodromou, Chrisostomos; Pearl, Laurence H

Nature Chemical Biology. May2013, Vol. 9 Issue 5, p307-312. 6p. 2 Black and White Photographs, 3 Graphs.

Clarke, Paul A; Hostein, Isabelle; Banerji, Udai; Stefano, Francesca Di; Maloney, Alison; Walton, Mike; Judson, Ian; Workman, Paul

Oncogene. 8/24/2000, Vol. 19 Issue 36, p4125. 9p.

Ravi S; Department of Chemistry, University of York, Heslington, York, UK, YO10 5DD. ian.fairlamb@york.ac.uk.; Maddocks CJ; Department of Chemistry, University of York, Heslington, York, UK, YO10 5DD. ian.fairlamb@york.ac.uk.; Fairlamb IJS; Department of Chemistry, University of York, Heslington, York, UK, YO10 5DD. ian.fairlamb@york.ac.uk.; Unsworth WP; Department of Chemistry, University of York, Heslington, York, UK, YO10 5DD. ian.fairlamb@york.ac.uk.; Clarke PA; Department of Chemistry, University of York, Heslington, York, UK, YO10 5DD. ian.fairlamb@york.ac.uk.

Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101154995 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-0539 (Electronic) Linking ISSN: 14770520 NLM ISO Abbreviation: Org Biomol Chem Subsets: MEDLINE; PubMed not MEDLINE

Zhang C; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Shanghai Institute of Biological Products, Shanghai, China.; Lu YJ; Guangdong Medicine-Engineering Interdisciplinary Technology Research Centre, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.; Wang M; Shanghai Institute of Biological Products, Shanghai, China.; Chen B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.; Xiong F; Shanghai Institute of Biological Products, Shanghai, China.; Mitsopoulos C; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Rossanese O; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.; Li X; Shanghai Institute of Biological Products, Shanghai, China. lixiuling@sinopharm.com.; Clarke PA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK. paul.clarke@icr.ac.uk.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE

Jeanmard L; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Lodovici G; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; George I; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Bray JTW; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Whitwood AC; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Thomas GH; Department of Biology, University of York, Heslington, York, YO10 5DD, UK.; Fairlamb IJS; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Unsworth WP; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.; Clarke PA; Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK. ian.fairlamb@york.ac.uk.

Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 9610838 Publication Model: Electronic Cited Medium: Internet ISSN: 1364-548X (Electronic) Linking ISSN: 13597345 NLM ISO Abbreviation: Chem Commun (Camb) Subsets: MEDLINE; PubMed not MEDLINE

Clarke, Paul A ; Holton, Robert A ; Kayaleh, Nadim E

In Tetrahedron Letters 2000 41(15):2687-2690

Poon E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Liang T; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.; Jamin Y; Division of Radiotherapy and Imaging, ICR, London, United Kingdom.; Walz S; Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany.; Kwok C; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Hakkert A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Barker K; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Urban Z; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Thway K; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom.; Zeid R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Hallsworth A; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Box G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Ebus ME; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands.; Licciardello MP; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Sbirkov Y; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Lazaro G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Calton E; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Costa BM; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Valenti M; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; De Haven Brandon A; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Webber H; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Tardif N; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Almeida GS; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Division of Radiotherapy and Imaging, ICR, London, United Kingdom.; Christova R; Division of Clinical Studies and.; Boysen G; Division of Clinical Studies and.; Richards MW; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.; Barone G; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Ford A; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom.; Bayliss R; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.; Clarke PA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; De Bono J; Division of Clinical Studies and.; Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Blagg J; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Robinson SP; Division of Radiotherapy and Imaging, ICR, London, United Kingdom.; Eccles SA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Zheleva D; Cyclacel Ltd., Dundee, United Kingdom.; Bradner JE; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Molenaar J; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands.; Vivanco I; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Eilers M; Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany.; Workman P; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.; Lin CY; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.; Chesler L; Division of Clinical Studies and.; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.

Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

Frame S; Cyclacel Limited, Dundee, United Kingdom.; Saladino C; Cyclacel Limited, Dundee, United Kingdom.; MacKay C; Cyclacel Limited, Dundee, United Kingdom.; Atrash B; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Sheldrake P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; McDonald E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Clarke PA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.; Blake D; Cyclacel Limited, Dundee, United Kingdom.; Zheleva D; Cyclacel Limited, Dundee, United Kingdom.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Pasqua AE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Sharp SY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Chessum NEA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Hayes A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Pellegrino L; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Tucker MJ; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Miah A; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Wilding B; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Evans LE; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Rye CS; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Mok NY; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Liu M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Henley AT; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Gowan S; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; De Billy E; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Te Poele R; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Powers M; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Eccles SA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Clarke PA; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Raynaud FI; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Workman P; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Jones K; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.; Cheeseman MD; Centre for Cancer Drug Discovery and Division of Cancer Therapeutics at The Institute of Cancer Research, London SW7 3RP, United Kingdom.

Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

Samant RS; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom. Electronic address: rahul.samant@babraham.ac.uk.; Batista S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom.; Larance M; Centre for Gene Regulation & Expression, University of Dundee, Dundee, United Kingdom.; Ozer B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom.; Milton CI; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom.; Bludau I; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.; Wu E; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom.; Biggins L; Bioinformatics Group, The Babraham Institute, Cambridge, United Kingdom.; Andrews S; Bioinformatics Group, The Babraham Institute, Cambridge, United Kingdom.; Hervieu A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom.; Johnston HE; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom.; Al-Lazikhani B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Lamond AI; Centre for Gene Regulation & Expression, University of Dundee, Dundee, United Kingdom.; Clarke PA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom.; Workman P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom. Electronic address: paul.workman@icr.ac.uk.

Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 101125647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-9484 (Electronic) Linking ISSN: 15359476 NLM ISO Abbreviation: Mol Cell Proteomics Subsets: MEDLINE

Whittaker SR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Barlow C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Martin MP; Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK.; Mancusi C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Wagner S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Self A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Barrie E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Te Poele R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Sharp S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Brown N; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Wilson S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Jackson W; Cyclacel Ltd., Dundee, UK.; Fischer PM; Cyclacel Ltd., Dundee, UK.; Clarke PA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; McDonald E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Noble M; Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK.; Garrett MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.

Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE